Case Based - Overview
Role of KRAS Status in Metastatic Colorectal Cancer
Release Date: December 29, 2008
Expiration Date: December 29, 2009
Interactive Case Study Overview
The high prevalence of epidermal growth factor receptor (EGFR) overexpression (≤ 75%) in colorectal tumors prompted the development of EGFR-targeted agents, including monoclonal antibodies (MoAbs), designed to inhibit receptor function. Anti-EGFR MoAbs have had a substantial impact in altering the treatment landscape for metastatic colorectal cancer (CRC) and have consistently benefited a subset of this patient population. Defining the subset of patients with metastatic CRC that benefits from EGFR-targeted therapy has remained a focus of clinical investigation, and recent data from randomized clinical trials have demonstrated that KRAS mutation status in the tumor has prognostic and/or predictive value regarding treatment with EGFR-targeted MoAbs. Review of the relevant clinical trial data in the context of a case study that follows an individual patient across multiple lines of therapy will support physicians in devising individualized therapeutic strategies for patients with metastatic CRC based, in part, on the tumor genetic profile. In addition, expert commentary on treatment options will help clarify the relevance of clinical trial data to current clinical practice in community oncology.
The purpose of this activity is to update physicians on the current standards regarding KRAS mutation analysis and the role of anti-EGFR MoAbs in treating patients with metastatic CRC.
Target Audience
This educational activity is intended for medical oncologists involved in the care of patients with CRC. No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity.
Learning Objectives
Upon completion of this educational activity, you should be able to:
- Select optimal treatments, including cytotoxic and biologic agents, for patients with newly diagnosed metastatic CRC based on data from phase III clinical trials
- Describe appropriate molecular tests for selecting EGFR-targeted therapy for patients with metastatic CRC
- Evaluate potential outcomes based on KRAS mutation status for patients with refractory metastatic CRC
Instructions for Participation
- Read the following information before beginning the educational activity.
- Complete the Pretest.
- Study the educational activity.
- Complete the CME test.
- Answer the evaluation questions.
- After successful completion of the CME test and evaluation, you will receive your certificate online.
Successful completion is determined by a score of 67% or greater.
You will be asked to login
or create an account.